Arrowhead Pharmaceuticals earnings spark fresh look at the stock

Arrowhead Pharmaceuticals (ARWR) recently reported third quarter 2026 results that showed sales of US$75.25 million alongside a net loss of US$194.28 million, drawing fresh attention to the stock.

Arrowhead Pharmaceuticals shares now trade at US$89.24, with a 30 day share price return of 16.81% and a year to date share price return of 31.64%. The 1 year total shareholder return of 401.35% indicates significant recent momentum in the stock as investors react to higher quarterly sales alongside larger reported losses.

If Arrowhead Pharmaceuticals has you looking at healthcare opportunities more broadly, this could be a moment to scan for other fast moving biotech and medical AI stories through the 43 healthcare AI stocks.

After a sharp rerating on mixed earnings, Arrowhead Pharmaceuticals now sits at a sizeable discount to both analyst targets and some fair value estimates. Is the market being careful for good reason, or is it behind the curve?

Most Popular Narrative: 20% Overvalued

Compared with the most followed fair value estimate of $89.08, Arrowhead Pharmaceuticals at $89.24 sits almost exactly in line with that model, which frames how some investors are thinking about the recent rally.

Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, positions the company to capitalize on rising demand for innovative treatments driven by an aging population and increasing prevalence of chronic and genetic diseases, which could significantly accelerate revenue growth as approvals and launches materialize.

Curious what kind of revenue curve and profit margins sit behind that fair value for Arrowhead Pharmaceuticals. The narrative leans on aggressive top line growth, a sharp swing in profitability and a rich future earnings multiple that is more often associated with established sector leaders. The underlying model also assumes a particular path for cash flows using a 7.33% discount rate. The interesting part is how those pieces combine to justify the analysts' target.

Result: Fair Value of $89.08 (ABOUT RIGHT)

However, Arrowhead Pharmaceuticals still faces meaningful risks, including heavy reliance on milestone payments and the possibility of clinical or regulatory setbacks that would challenge this upbeat narrative.

Another View on Arrowhead Pharmaceuticals Valuation

The first take on Arrowhead Pharmaceuticals focused on fair value around $89.08 based on future earnings and margins. Our DCF model points in a different direction. At $89.24, Arrowhead is trading at about a 49% discount to an estimated future cash flow value of $174.62, which suggests a much richer long term potential if those cash flows arrive as modeled.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Arrowhead Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of risks and rewards around Arrowhead Pharmaceuticals can feel finely balanced, so it helps to move quickly and test the assumptions against your own expectations. To see how those concerns and potential upsides line up in detail, take a close look at the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Arrowhead Pharmaceuticals?

If Arrowhead Pharmaceuticals has sharpened your focus, do not stop here. Broader research gives you more options and helps you spot opportunities others might overlook.

• Target potential mispricings by scanning 49 high quality undervalued stocks that combine solid fundamentals with room for sentiment to shift.
• Strengthen your income stream by reviewing 8 dividend fortresses that offer higher yields with clear payout track records.
• Prioritize resilience by focusing on 85 resilient stocks with low risk scores that score well on financial stability and business risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.